Mirum Pharmaceuticals (NASDAQ:MIRM) will be posting its quarterly earnings results after the market closes on Thursday, May 6th. Analysts expect Mirum Pharmaceuticals to post earnings of ($0.67) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Monday, March 8th. The company reported ($1.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.70). On average, analysts expect Mirum Pharmaceuticals to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Shares of MIRM traded down $0.90 during midday trading on Tuesday, hitting $18.89. The stock had a trading volume of 43 shares, compared to its average volume of 131,009. The business has a 50-day simple moving average of $19.13 and a two-hundred day simple moving average of $19.35. The firm has a market cap of $575.05 million, a P/E ratio of -5.75 and a beta of 2.44. Mirum Pharmaceuticals has a fifty-two week low of $14.94 and a fifty-two week high of $27.43.

MIRM has been the topic of several research analyst reports. Robert W. Baird reiterated a “buy” rating and set a $30.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, April 1st. SVB Leerink began coverage on Mirum Pharmaceuticals in a research note on Monday, February 8th. They issued an “outperform” rating and a $38.00 price objective for the company. Finally, Zacks Investment Research raised Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, April 9th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $37.57.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.

Recommended Story: Accumulation/Distribution

Earnings History for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.